Literature DB >> 29057428

Pain Quality Assessment Scale for Epidermolysis Bullosa.

Nicholas H B Schräder1, Wing Y Yuen, Marcel F Jonkman.   

Abstract

Pain is one of the most debilitating symptoms in epidermolysis bullosa (EB) leading to reduced quality of life. Pain in EB comprises both neuropathic and non-neuropathic qualities. An assessment of pain qualities has not formerly been completed in EB. The Pain Quality Assessment Scale (PQAS) is an adjusted version of the validated Neuropathic Pain Scale and includes 20 pain qualities and descriptors. Patients with EB (n = 43) rated the pain qualities in the PQAS on 20 numerical scales and 1 multiple choice question. Pain was experienced by 39 patients (91%). In general, patients with EB experience intense and unpleasant pain on the surface of the skin; the hands and feet are most commonly affected. The subtypes, recessive dystrophic EB and junctional EB reported pain qualities pathognomonic of neuropathic pain. The PQAS adds value to the current practice of global pain intensity scoring in EB.

Entities:  

Mesh:

Year:  2018        PMID: 29057428     DOI: 10.2340/00015555-2827

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

Review 1.  Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines.

Authors:  K Martin; S Geuens; J K Asche; R Bodan; F Browne; A Downe; N García García; G Jaega; B Kennedy; P J Mauritz; F Pérez; K Soon; V Zmazek; K M Mayre-Chilton
Journal:  Orphanet J Rare Dis       Date:  2019-06-11       Impact factor: 4.123

Review 2.  A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.

Authors:  Jean Yuh Tang; M Peter Marinkovich; Eleanor Lucas; Emily Gorell; Albert Chiou; Ying Lu; Jodie Gillon; Dipen Patel; Dan Rudin
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

3.  Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases.

Authors:  N H B Schräder; J C Duipmans; B Molenbuur; A P Wolff; M F Jonkman
Journal:  Br J Dermatol       Date:  2018-11-14       Impact factor: 9.302

4.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.